Anna Chen Arroyo
Clinical Associate Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine
Bio
Dr. Arroyo specializes in the treatment of allergic conditions including drug allergy and asthma. She has a special interest in understanding health and healthcare disparities in allergic diseases and how allergies change over a person's lifetime.
Clinical Focus
- Allergy and Immunology
- Drug allergy
- Asthma
Academic Appointments
-
Clinical Associate Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine
Administrative Appointments
-
Section Chief, Allergy, Asthma, and Immunodeficiency, Division of Pulmonary, Allergy, and Critical Care Medicine (2024 - Present)
-
Medical Director, Allergy, Asthma, & Immunodeficiency Clinic, Stanford Health Care (2020 - Present)
Professional Education
-
Medical Education: Stanford University School of Medicine (2012) CA
-
Fellowship: Brigham and Women's Hospital Allergy and Immunology Fellowship (2019) MA
-
Board Certification: American Board of Allergy and Immunology, Allergy and Immunology (2018)
-
Board Certification: American Board of Internal Medicine, Internal Medicine (2015)
-
Residency: Stanford University Internal Medicine Residency (2015) CA
-
MPH, University of California at Berkeley (2012)
All Publications
-
Allergic disease prevalence among Asian American children in Northern California.
The journal of allergy and clinical immunology. In practice
2024
View details for DOI 10.1016/j.jaip.2024.08.040
View details for PubMedID 39197749
-
Greenhouse Gas Emissions and Costs of Inhaler Devices in the US.
JAMA
2024
View details for DOI 10.1001/jama.2024.15331
View details for PubMedID 39207797
View details for PubMedCentralID PMC11362968
-
Ethnic Variation in Asthma Prevalence across Childhood in the Asian American and Pacific Islander Population.
Chest
2024
View details for DOI 10.1016/j.chest.2024.07.170
View details for PubMedID 39181377
-
Social Determinants of Health and Allergic Disease Prevalence Among Asian American Children.
Journal of racial and ethnic health disparities
2024
Abstract
Although racial and ethnic disparities in allergic diseases have previously been observed, the relationship between social determinants of health (SDoH) and allergic disease prevalence among disaggregated Asian American (AsA) subgroups is poorly understood.To examine the association of SDoH with allergic disease prevalence among disaggregated AsA subgroups.Using the 2011-2018 National Health Interview Survey, we examined caregiver-reported race and ethnicity, SDoH, and allergic diseases. We compared survey-weighted allergic disease prevalence by AsA subgroup. Subgroup-stratified multivariable logistic regression accounting for age, sex, child/parent nativity, and survey year modeled the association between SDoH and allergic disease prevalence. We provide predicted probabilities of having each allergic disease based on exposure to each SDoH.We examined data from 5042 non-Hispanic AsA children representing 3,264,768 AsA children. Approximately 25% of all AsA children reported at least one allergic disease, ranging from 20% of Asian Indian children to 30% of Filipino/a children. The number of unfavorable SDoH was lowest among Asian Indian and Chinese children (mean 0.7) and highest among "other Asian" children (mean 1.2). In stratified analyses, financial instability and inaccessible healthcare were associated with greater probability of allergic diseases among some, but not all AsA subgroups. Lower parent education level, food insecurity, and rent/other housing arrangement were associated with lower probability of allergic disease among some AsA children.There was heterogeneity in the association of SDoH and allergic disease prevalence among AsA children. Further study of SDoH may inform modifiable environmental factors for allergic disease among AsA children.
View details for DOI 10.1007/s40615-024-01918-0
View details for PubMedID 38315290
View details for PubMedCentralID 9901425
-
Prevalence of allergic diseases among Asian American children in a Northern California healthcare system
MOSBY-ELSEVIER. 2024: AB250
View details for Web of Science ID 001267526000772
-
Predicting Penicillin Allergy from PatientReported Data: A Multi-Site Prospective Study from The United States Drug Allergy Registry
MOSBY-ELSEVIER. 2024: AB228
View details for Web of Science ID 001267526000704
-
PEN-FAST Assessment Using Patient-Reported Reaction Histories in a Multi-Site Prospective United States Cohort
MOSBY-ELSEVIER. 2024: AB241
View details for Web of Science ID 001267526000744
-
Asthma heterogeneity amongst Asian American children: the California Health Interview Survey.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
2023
Abstract
The Asian American (AsA) population is heterogenous and rapidly growing; however, little is known regarding childhood asthma burden amongst AsA ethnic groups. The relation of obesity and asthma among AsA ethnic groups also remains unclear.To evaluate asthma prevalence and the relation of obesity to asthma risk amongst children in seven AsA ethnic groups.We analyzed data from the California Health Interview Survey from 2011-2020. AsA ethnicities were self-reported. Body mass index (BMI) z-scores, calculated from self-reported height/weight, were used to categorize children by obesity status, based on BMI-for-age growth charts. Prevalence of self-reported lifetime doctor-diagnosed asthma and asthma attack in the last 12 months were calculated. We performed multivariable logistic regressions adjusting for age and sex.Of 34,146 survey respondents, 12.2% Non-Hispanic White (NHW) and 12.5% AsA children reported lifetime asthma. Among AsA ethnic groups, however, lifetime asthma ranged from 5.1% (Korean American) to 21.5% (Filipino American). Compared to NHW children, AsA children had a similar lifetime asthma prevalence (aOR=1.05; 95%CI: 0.71-1.55; p=0.81), but lower prevalence in Korean American children (aOR 0.37; 95%CI, 0.19-0.73; p=0.004) and higher prevalence in Filipino American children (aOR 1.97; 95%CI, 1.22-3.17; p=0.006). The lifetime asthma prevalence of different AsA ethnic groups persisted even when stratified by obesity status.Childhood lifetime asthma prevalence varied among AsA ethnic groups, with lowest prevalence among Korean American children and highest prevalence among Filipino American. Further characterization of asthma burden amongst AsA ethnic groups may help guide asthma screening and prevention measures and offer new insights into asthma pathogenesis.
View details for DOI 10.1016/j.anai.2023.10.030
View details for PubMedID 37949352
-
Risk of Incident Asthma among Young Asian American, Native Hawaiian, and Pacific Islander Children from Age 3 to 7 years in a Northern California Healthcare System.
The Journal of pediatrics
2023: 113802
Abstract
Incident childhood asthma risk has not been examined among diverse Asian American, Native Hawaiian, and Pacific Islander subgroups. In a large California healthcare system, incident asthma was higher among young Filipino/a, Native Hawaiian/Pacific Islander, and South Asian children compared with Non-Hispanic White children, whereas Chinese and Japanese children were similar.
View details for DOI 10.1016/j.jpeds.2023.113802
View details for PubMedID 37898424
-
Maternal Hypertensive Disorders of Pregnancy and the Risk of Childhood Asthma
ANNALS OF THE AMERICAN THORACIC SOCIETY
2023; 20 (9): 1367-1370
View details for Web of Science ID 001064160400024
View details for PubMedID 37233740
View details for PubMedCentralID PMC10502887
-
Association between severe bronchiolitis in infancy and age 6-year lung function.
Respiratory medicine
2023: 107401
Abstract
BACKGROUND AND OBJECTIVES: Understanding early life risk factors for decreased lung function could guide prevention efforts and improve lung health throughout the lifespan. Our objective was to investigate the association between history of severe (hospitalized) bronchiolitis in infancy and age 6-year lung function.METHODS: We analyzed data from two prospective cohort studies: infants hospitalized with bronchiolitis and a parallel cohort of healthy infants. Children were followed longitudinally, and spirometry was performed at age 6 years. To examine the relationship between history of severe bronchiolitis and primary outcomes - FEV1% predicted (pp) and FEV1/FVCpp - we used multivariable linear regression models adjusted for insurance status, perterm birth, secondhand smoke exposure, breastfeeding status, traffic-related air pollution and polygenic risk score. Secondary outcomes included FVCpp and bronchodilator responsiveness (BDR).RESULTS: Age 6-year spirometry was available for 425 children with history of severe bronchiolitis in infancy and 48 controls. Unadjusted analysis revealed that while most children had normal range lung function, children with a history of severe bronchiolitis had lower FEV1pp and FEV1/FVCpp. In adjusted analyses, the same findings were observed: FEV1pp was 8% lower (p = 0.004) and FEV1/FVCpp was 4% lower (p = 0.007) in children with history of severe bronchiolitis versus controls. FVC and BDR did not differ between groups.CONCLUSIONS: Children with severe bronchiolitis in infancy have decreased FEV1 and FEV1/FVC at age 6 years, compared to controls. These children may be at increased risk for chronic respiratory illness later in life.
View details for DOI 10.1016/j.rmed.2023.107401
View details for PubMedID 37657534
-
US Drug Allergy Registry (USDAR) grading scale for immediate drug reactions.
The Journal of allergy and clinical immunology
2023
Abstract
There is no accepted grading system classifying the severity of immediate reactions to drugs.The purpose of this article is to present a proposed grading system developed through the consensus of drug allergy experts from the US Drug Allergy Registry (USDAR) Consortium.The USDAR investigators sought to develop a consensus severity grading system for immediate drug reactions that is applicable to clinical care and research.The USDAR grading scale scores severity levels on a scale of 0 to 4. A grade of no reaction (NR) is used for patients who undergo challenge without any symptoms or signs, and it would confirm a negative challenge result. A grade 0 reaction is indicative of primarily subjective complaints that are commonly seen with both historical drug reactions and during drug challenges, and it would suggest a low likelihood of a true drug allergic reaction. Grades 1 to 4 could meet the criteria for a positive challenge result and be considered indicative of a drug allergy. Grade 1 reactions are suggestive of a potential immediate drug reaction with mild symptoms. Grade 2 reactions are more likely to be immediate drug reactions of moderate severity. Grade 3 reactions have features suggestive of a severe allergic reaction, whereas grade 4 reactions are life-threatening reactions such as anaphylactic shock and fatal anaphylaxis.This proposed grading schema for immediate drug reactions improves on prior schemata by being developed specifically for immediate drug reactions and being user-friendly and easy to implement in clinical and research practice.
View details for DOI 10.1016/j.jaci.2023.08.018
View details for PubMedID 37652140
-
The relation of prenatal acid suppressant medication exposure to severe bronchiolitis and childhood asthma.
Pediatric pulmonology
2023
View details for DOI 10.1002/ppul.26638
View details for PubMedID 37594143
-
Asthma heterogeneity amongst Asian American children: the California Health Interview Survey
MOSBY-ELSEVIER. 2023: AB75
View details for Web of Science ID 000991651900228
-
Cohort study of early life environmental factors and risk of decreased lung function at age 6 years in children with a history of severe bronchiolitis
MOSBY-ELSEVIER. 2023: AB116
View details for Web of Science ID 000991651900359
-
Maternal exposures to acid suppressant medications or antibiotics and infant food allergy in a bronchiolitis cohort
MOSBY-ELSEVIER. 2023: AB173
View details for Web of Science ID 000991651900529
-
Cohort Study of Maternal Gestational Weight Gain, Gestational Diabetes, and Childhood Asthma.
Nutrients
2022; 14 (23)
Abstract
Data on the association of maternal gestational weight gain (GWG) and gestational diabetes mellitus (GDM) with childhood asthma are limited and inconsistent. We aimed to investigate these associations in a U.S. pre-birth cohort. Analyses included 16,351 mother-child pairs enrolled in the Massachusetts General Hospital Maternal-Child Cohort (1998-2010). Data were obtained by linking electronic health records for prenatal visits/delivery to determine BMI, GWG, and GDM (National Diabetes Data Group criteria) and to determine asthma incidence and allergies (atopic dermatitis or allergic rhinitis) for children. The associations of prenatal exposures with asthma were evaluated using logistic regression adjusted for maternal characteristics. A total of 2306 children (14%) developed asthma by age 5 years. Overall, no association was found between GWG and asthma. GDM was positively associated with offspring asthma (OR 1.46, 95% CI 1.14-1.88). Associations between GDM and asthma were observed only among mothers with early pregnancy BMI between 20 and 24.9 kg/m2 (OR 2.31, CI 1.46-3.65, p-interaction 0.02). We report novel findings on the impact of prenatal exposures on asthma, including increased risk among mothers with GDM, particularly those with a normal BMI. These findings support the strengthening of interventions targeted toward a healthier pregnancy, which may also be helpful for childhood asthma prevention.
View details for DOI 10.3390/nu14235188
View details for PubMedID 36501218
View details for PubMedCentralID PMC9741125
-
No allergy left behind The importance of food allergy in longitudinal cohorts
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
2022; 129 (2): 140-141
View details for Web of Science ID 000929478000007
-
Infant exposure to acid suppressant medications increases risk of recurrent wheeze and asthma in childhood.
The journal of allergy and clinical immunology. In practice
2022
Abstract
BACKGROUND: Acid suppressant medications (ASMs) are commonly prescribed in infancy. Little is known about the relationship between ASM exposure and risk of childhood asthma and atopic conditions.OBJECTIVE: We sought to examine the association between infant ASM exposure and risk for developing recurrent wheeze, allergen sensitization, and asthma in early childhood.METHODS: We used data from a diverse, multi-center, prospective cohort study of 921 infants with a history of bronchiolitis. ASM exposure (histamine-2 receptor antagonists and/or proton pump inhibitors) during infancy (age <12 months) was ascertained by parent report and medical record review. The outcomes were recurrent wheeze by age 3 years, early childhood allergen sensitization (serum specific IgE), and asthma by age 6 years. We constructed multivariable Cox proportional hazards models and multivariable logistic regression models adjusting for multiple confounders.RESULTS: Of the 921 children in the cohort, 202 (22%) were exposed to ASMs during infancy. Compared to unexposed children, those exposed to ASM were more likely to develop recurrent wheeze by age 3 years (adjusted hazard ratio 1.58, 95%CI 1.20-2.08, P=0.001) and asthma by age 6 years (adjusted odds ratio 1.66, 95%CI 1.22-2.27, P=0.001). ASM exposure during infancy was not significantly associated with the development of early childhood allergen sensitization (adjusted odds ratio 1.00, 95%CI 0.70-1.44, P=0.99).CONCLUSIONS: While exposure to ASMs during infancy does not increase the risk of allergen sensitization in early childhood, ASM exposure during infancy increases the risk of recurrent wheeze and asthma during early childhood.
View details for DOI 10.1016/j.jaip.2022.07.013
View details for PubMedID 35872214
-
The importance of understanding anaphylaxis among older adults.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
2022; 129 (1): 7-8
View details for DOI 10.1016/j.anai.2022.04.024
View details for PubMedID 35717136
-
Asian American Patients With Allergic Diseases: Considerations for Research and Clinical Care.
The journal of allergy and clinical immunology. In practice
2022; 10 (4): 950-952
View details for DOI 10.1016/j.jaip.2022.01.031
View details for PubMedID 35397816
-
Prenatal exposure to acid suppressant medications and risk of allergen sensitization.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
2022; 33 (3): e13760
View details for DOI 10.1111/pai.13760
View details for PubMedID 35338744
-
Maternal hypertensive disorders of pregnancy and the risk of childhood asthma
MOSBY-ELSEVIER. 2022: AB88
View details for Web of Science ID 000778999300264
-
Road Less Traveled: Drug Hypersensitivity to Fluoroquinolones, Vancomycin, Tetracyclines, and Macrolides.
Clinical reviews in allergy & immunology
1800
Abstract
While fluoroquinolones, vancomycin, macrolides, and tetracyclines are generally safe antibiotics, they can induce both immediate and delayed hypersensitivity reactions (HSRs). Historically, less has been published on allergies to these antibiotics compared to beta lactams, but the prevalence of non-beta lactam HSRs is increasing. To fluoroquinolones, immediate HSRs are more common than delayed reactions. Both IgE and non-IgE mechanisms, such as the mast cell receptor Mas-related G protein-coupled receptor X2 (MRGPRX2), have been implicated in fluoroquinolone-induced anaphylaxis. Skin testing for fluoroquinolones is controversial, and the gold standard for diagnosis is a graded dose challenge. To vancomycin, the most common reaction is vancomycin infusion reaction (previously called "red man syndrome"), which is caused by infusion rate-dependent direct mast cell degranulation. Severity can range from flushing and pruritis to angioedema, bronchospasm, and hypotension that mimic type I HSRs. MRGPRX2 has been implicated in vancomycin infusion reactions. IgE-mediated HSRs to vancomycin are rare. Vancomycin skin testing yields high false positive rates. Thus, direct provocation challenge with slower infusion rate and/or antihistamine pre-treatment is preferred if symptoms are mild to moderate, and desensitization can be considered if symptoms are severe. To tetracyclines, non-IgE-mediated and delayed HSRs predominate with cutaneous reactions being the most common. There is no standardized skin testing for tetracyclines, and avoidance is generally recommended after a severe reaction because of the paucity of data for testing. Graded dose challenges and desensitizations can be considered for alternative or index tetracyclines if there are no alternatives. With macrolides, urticaria/angioedema is the most common immediate HSR, and rash is the most common delayed HSR. The predictive value for skin testing to macrolides is similarly poorly defined. In general, HSRs to fluroquinolones, vancomycin, macrolides, and tetracyclines are challenging to diagnose given the lack of validated skin testing and in vitro testing. Direct provocation challenge remains the gold standard for diagnosis, but the benefits of confirming an allergy may not outweigh the risk of a severe reaction. Skin testing, direct provocation challenge, and/or desensitization to the index non-beta lactam antibiotic or alternatives in its class may be reasonable approaches depending on the clinical context and patient preferences.
View details for DOI 10.1007/s12016-021-08919-5
View details for PubMedID 35092578
-
No allergy left behind - the importance of food allergy in longitudinal cohorts.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
2021
View details for DOI 10.1016/j.anai.2021.12.002
View details for PubMedID 34879264
-
Emergency department visits for vaccine-related severe allergic reactions among US adults: 2006-2018.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
2021
View details for DOI 10.1016/j.anai.2021.11.017
View details for PubMedID 34863951
-
Early Introduction of Food Allergens and Risk of Developing Food Allergy
NUTRIENTS
2021; 13 (7)
View details for DOI 10.3390/nu13072318
View details for Web of Science ID 000676656300001
-
Emergency department revisits and rehospitalizations among infants and toddlers for acute allergic reactions.
Allergy and asthma proceedings
2021; 42 (3): 247–56
Abstract
Background and Objective: Allergic reactions, including anaphylaxis, are rising among children. Little is known about health care utilization among infants and toddlers. Our objective was to characterize health care utilization and charges for acute allergic reactions (AAR). Methods: We conducted a retrospective cohort study of trends in emergency department (ED) visits and revisits, hospitalizations and rehospitalizations, and charges among infants and toddlers (ages < 3 years), with an index ED visit or hospitalization for AAR (including anaphylaxis). We used data from population-based multipayer data: State Emergency Department Databases and State Inpatient Databases from New York and Nebraska. Multivariable logistic regression was used to identify factors associated with ED revisits and rehospitalizations. Results: Between 2006 and 2015, infant and toddler ED visits for AAR increased from 27.8 per 10,000 population to 35.2 (Ptrend < 0.001), whereas hospitalizations for AAR remained stable (Ptrend = 0.11). In the one year after an index AAR visit, 5.1% of these patients had at least one AAR ED revisit and 5.9% had at least one AAR rehospitalization. Factors most strongly associated with AAR ED revisits included an index visit hospitalization and receipt of epinephrine. Total charges for AAR ED visits (2009-2015) and hospitalizations (2011-2015) were more than $29 million and $11 million, respectively. Total charges increased more than fourfold for both AAR ED revisits for AAR rehospitalizations during the study period. Conclusion: Infants and toddlers who presented with an AAR were at risk for ED revisits and rehospitalizations for AAR within the following year. The charges associated with these revisits were substantial and seemed to be increasing.
View details for DOI 10.2500/aap.2021.42.210031
View details for PubMedID 33980339
-
Trends in emergency department visits and hospitalizations for acute allergic reactions and anaphylaxis among US older adults: 2006-2014.
The journal of allergy and clinical immunology. In practice
2021
Abstract
BACKGROUND: The US older adult population (≥65 years) is increasing and may be at increased risk for severe anaphylaxis. Little is known about the healthcare utilization for acute allergic reactions (AAR), including anaphylaxis, among older adults.OBJECTIVES: To characterize trends in emergency department (ED) visits and hospitalizations for AAR and anaphylaxis among US older adults from 2006-2014, and to examine factors associated with severe anaphylaxis.METHODS: We performed cross-sectional analyses of trends in ED visits and hospitalizations among older adults using data from the Nationwide Emergency Department Sample and the National (Nationwide) Inpatient Sample in 2006-2014. We used International Classification of Diseases, Ninth Revision, Clinical Modification diagnostic codes to identify visits for AAR, including anaphylaxis. Multivariable logistic regression modeling was used to identify factors associated with severe anaphylaxis (cardiac arrest, intubation and death).RESULTS: In 2006-2014, older adults experienced approximately 1,019,967 AAR-related ED visits; 173,844 AAR-related hospitalizations; 93,795 anaphylaxis-related ED visits; and 72,677 anaphylaxis-related hospitalizations. While AAR-related ED visit and hospitalization rates remained stable (P-trends=0.28 and 0.16, respectively), anaphylaxis-related ED visit and hospitalization rates significantly increased over time (37 visits per 100,000 population in 2006 to 51 in 2014, P-trend<0.001; 13 hospitalizations per 100,000 population in 2006 to 23 in 2014, P-trend<0.001), especially hospitalization rates for drug-related anaphylaxis (47 hospitalizations per 100,000 population in 2006 to 85 in 2014, P-trend<0.001). Risk factors for anaphylaxis-related death included older age and drug-related trigger.CONCLUSIONS: In a nationally representative sample of US older adults, the rate of anaphylaxis-related ED visits and hospitalizations increased over time. Drug-related triggers represented a substantial portion of the increased healthcare utilization and are a growing risk in this vulnerable population.
View details for DOI 10.1016/j.jaip.2021.03.032
View details for PubMedID 33798790
-
Trends in U.S. emergency department visits for anaphylaxis among infants and toddlers: 2006-2015.
The journal of allergy and clinical immunology. In practice
2021
Abstract
BACKGROUND: Anaphylaxis is a potentially life-threatening allergic reaction. The overall prevalence of anaphylaxis appears to be rising in children, but temporal trends among infants and toddlers are not well studied.OBJECTIVE: To characterize the trends in U.S. emergency department (ED) visits and hospitalizations among infants and toddlers with anaphylaxis from 2006-2015.METHODS: We conducted a study of temporal trends in anaphylaxis among children (age <18 years) and, more specifically, infants and toddlers (age <3 years) presenting to the ED between 2006-2015 using a large, nationally representative database. For internal consistency, we defined anaphylaxis using ICD-9-CM diagnosis codes and excluded visits with ICD-10-CM (late 2015). We calculated trends in the number and proportion of ED visits and hospitalizations and used multivariable logistic regression to identify predictors of hospitalization.RESULTS: Among infants and toddlers, the proportion of ED visits for anaphylaxis per year increased from 20 per 100,000 visits to 50 per 100,000 visits (Ptrend <0.001). The rate of ED visits for anaphylaxis increased from 15 to 32 ED visits per 100,000 population of infants and toddlers (Ptrend <0.001). Food was the most commonly identified trigger. The proportion of hospitalization among anaphylaxis-related ED visits decreased from 19% to 6% (Ptrend <0.001). Among ED patients, those more likely to be hospitalized were male, privately insured, from higher income families, and presenting to urban, metropolitan teaching hospital EDs.CONCLUSION: In a large, nationally representative US database, from 2006 to 2015, ED visits by infants and toddlers with anaphylaxis increased, while hospitalization of these patients decreased.
View details for DOI 10.1016/j.jaip.2021.01.010
View details for PubMedID 33486144
-
Evaluation of Allergic Diseases in Transgender and Gender-Diverse Patients: A Case Study of Asthma.
The journal of allergy and clinical immunology. In practice
2021
View details for DOI 10.1016/j.jaip.2021.10.035
View details for PubMedID 34782303
-
Trends in U.S. hospitalizations for anaphylaxis among infants and toddlers: 2006-2015.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
2020
Abstract
BACKGROUND: Anaphylaxis is a potentially fatal acute allergic reaction. Its overall prevalence appears to be rising, but little is known about U.S. hospitalization trends among infants and toddlers.OBJECTIVE: To identify the trends and predictors of hospitalization for anaphylaxis among infants and toddlers.METHODS: We used the nationally representative National Inpatient Sample (NIS), from 2006-2015, to perform an analysis of trends in U.S. hospitalizations for anaphylaxis among infants and toddlers (age <3 years) and other children (age 3-18 years). For internal consistency, we identified patients with anaphylaxis by ICD-9-CM diagnosis code and excluded those with ICD-10-CM (late 2015). We calculated trends in anaphylaxis hospitalizations over time by age group, then used multivariable logistic regression to describe anaphylaxis hospitalizations among infants and toddlers.RESULTS: Among infants and toddlers, there was no significant change in anaphylaxis hospitalizations during the 10-year study period (P trend =0.14). Anaphylaxis hospitalization among infants and toddlers was more likely in males, with private insurance, in the highest income quartile, with chronic pulmonary disease, who presented on a weekend day, to an urban teaching hospital, located in the Northeast. In contrast, anaphylaxis hospitalizations among older children (age 3 to <18 years) rose significantly during the study (P trend <0.001).CONCLUSION: Anaphylaxis hospitalizations among infants and toddlers in the US were stable from 2006-2015, while hospitalizations among older children were rising. Future research should focus on the trends in disease prevalence and healthcare utilization in the understudied population of infants and toddlers.
View details for DOI 10.1016/j.anai.2020.09.003
View details for PubMedID 32911059
-
Allergic sensitization during early life: Concordance between ImmunoCAP and ISAC results.
The journal of allergy and clinical immunology. In practice
2020
View details for DOI 10.1016/j.jaip.2020.12.028
View details for PubMedID 33359588
-
Prenatal exposure to acid-suppressant medications and the risk of recurrent wheeze at 3 years of age in children with a history of severe bronchiolitis.
The journal of allergy and clinical immunology. In practice
2019
View details for DOI 10.1016/j.jaip.2019.02.039
View details for PubMedID 30878709
-
Where do children die from asthma? National data from 2003 to 2015
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
2018; 6 (3): 1034–36
View details for PubMedID 28970087
View details for PubMedCentralID PMC5876061
-
Occupational exposures and asthma prevalence among US farmworkers: National Agricultural Workers Survey, 2003-2014.
The journal of allergy and clinical immunology. In practice
2018
View details for PubMedID 29626636
-
Staphylococcal infections in children, California, USA, 1985-2009.
Emerging infectious diseases
2013; 19 (1): 10-20
Abstract
We conducted a retrospective, observational, population-based study to investigate the effect of staphylococcal infections on the hospitalization of children in California during 1985-2009. Hospitalized children with staphylococcal infections were identified through the California Office of Statewide Health Planning and Development discharge database. Infections were categorized as community onset, community onset health care-associated, or hospital onset. Infection incidence was calculated relative to all children and to those hospitalized in acute-care facilities. A total of 140,265 records were analyzed. Overall incidence increased from 49/100,000 population in 1985 to a peak of 83/100,000 in 2006 and dropped to 73/100,000 in 2009. Staphylococcal infections were associated with longer hospital stays and higher risk for death relative to all-cause hospitalizations of children. The number of methicillin-resistant Staphylococcus aureus infections increased, and the number of methicillin-susceptible S. aureus infections remained unchanged. Children <3 years of age, Blacks, and those without private insurance were at higher risk for hospitalization.
View details for DOI 10.3201/eid1901.111740
View details for PubMedID 23260060
-
The association between insurance status and emergency department disposition of injured California children.
Academic emergency medicine
2012; 19 (5): 541-551
Abstract
This study examined the relationship between insurance status and emergency department (ED) disposition of injured California children.Multivariate regression models were built using data obtained from the 2005 through 2009 California Office of Statewide Health Planning and Development (OSHPD) data sets for all ED visits by injured children younger than 19 years of age.Of 3,519,530 injury-related ED visits, 52% were insured by private, and 36% were insured by public insurance, while 11% of visits were not insured. After adjustment for injury characteristics and demographic variables, publicly insured children had a higher likelihood of admission for mild, moderate, and severe injuries compared to privately insured children (mild injury adjusted odds ratio [AOR] = 1.36, 95% confidence interval [CI] = 1.34 to 1.39; moderate and severe injury AOR = 1.34, 95% CI = 1.28 to 1.41). However, uninsured children were less likely to be admitted for mild, moderate, and severe injuries compared to privately insured children (mild injury AOR = 0.63, 95% CI = 0.61 to 0.66; moderate and severe injury AOR = 0.50, 95% CI = 0.46 to 0.55). While publicly insured children with moderate and severe injuries were as likely as privately insured children to experience an ED death (AOR = 0.91, 95% CI = 0.70 to 1.18), uninsured children with moderate and severe injuries were more likely to die in the ED compared to privately insured children (AOR = 3.11, 95% CI = 2.38 to 4.06).Privately insured, publicly insured, and uninsured injured children have disparate patterns of ED disposition. Policy and clinical efforts are needed to ensure that all injured children receive equitable emergency care.
View details for DOI 10.1111/j.1553-2712.2012.01356.x
View details for PubMedID 22594358
View details for PubMedCentralID PMC3443629